ACTINIUM PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $90.0K | — | $81.0K | $1.0M | $1.1M | — | — |
| Cost of Revenue | — | — | — | — | — | $900.0K | — | — |
| Gross Profit | — | — | — | — | — | $244.0K | — | — |
| Gross Margin | — | — | — | — | — | 21.3% | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $21.1M | $30.0M | $38.7M | $23.1M | $18.0M | $16.1M | $16.6M |
| SG&A Expense | — | $15.2M | $12.1M | $13.3M | $12.0M | $8.1M | $6.3M | $5.5M |
| Operating Income | — | $-36.2M | $-42.1M | $-51.9M | $-34.1M | $-25.0M | $-22.4M | $-22.1M |
| Operating Margin | — | -40,274.4% | — | -64,098.8% | -3,311.1% | -2,182.2% | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-33.9M | $-38.2M | $-48.8M | $-33.0M | $-24.8M | $-22.2M | $-21.9M |
| Net Margin | — | -37,652.2% | — | -60,269.1% | -3,205.5% | -2,165.6% | — | — |
| EPS (Basic) | — | $-1.09 | $-1.27 | $-1.83 | $-1.37 | $-1.20 | $-1.83 | $-4.40 |
| EPS (Diluted) | — | $-1.09 | $-1.27 | $-1.83 | $-1.37 | $-1.20 | $-1.83 | $-4.40 |
| Shares Outstanding (Basic) | 31.4M | 31.2M | 30.1M | 26.6M | 24.1M | 20.6M | 17.5M | 5.5M |
| Shares Outstanding (Diluted) | 31.4M | 31.2M | 30.1M | 26.6M | 24.1M | 20.6M | 17.5M | 5.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |